Navigation Links
TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R))
Date:1/15/2014

s for CAP and acute bacterial skin and skin structure infections (ABSSSI). TaiGen owns the worldwide patent portfolio of nemonoxacin that protects composition, use, and processes until 2029.

"We are very excited about the opportunity to bring this truly innovative anti-infective compound to patients in Russia, other former Soviet Union states, and Turkey and will use our clinical, regulatory and commercial capabilities to ensure speedy registration and successful launch," said Vasily G. Ignatiev, CEO of R-Pharm.

Dr. Ming-Chu Hsu, President and Chief Executive Officer of TaiGen, said, "We are very impressed with the R-Pharm's experience and their commitment to infectious diseases. The Russian Federation and Turkey are among the world's top twenty pharmaceutical markets and their growth in the next five years will outpace the U.S., EU and Japan, according to IMS. Both countries also have a very high incidence of drug-resistance bacterial infections.Together we can bring innovative medicines such as nemonoxacin to these areas where the medical need is very high."

About R-Pharm

R-Pharm is a leading Russian pharmaceutical company with commercial operations in the Russian Federation, CIS, and Turkey.  In 2013, it has over 2,800 employees with sales revenue of US$1.8 billion. Key business areas of R-Pharm include manufacturing, sales and marketing of prescription drugs, laboratory diagnostics, medical equipment, and venture investment.

About TaiGen Biotechnology

TaiGen Biotechnology is a leading research-based and product-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, China. In addition to nemon
'/>"/>

SOURCE TaiGen Biotechnology Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Puma Biotechnology Announces Completion of Private Placement
2. Animal Biotechnology - Technologies, Markets and Companies
3. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
4. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
5. JumpStart Invests $250,000 in Milo Biotechnology
6. Global Biotechnology Industry
7. Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004
8. Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
9. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
10. Global Biotechnology Instrumentation Industry
11. Choose New Jersey, Inc. to Tout New Jerseys Life Sciences Hub At Worlds Largest Biotechnology Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest international ... medicinal plants and therapeutic derivatives thereof has endorsed ... and researchers about the challenges of adulterated herb ... ) The Society for Medicinal ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Germany will present itself as one of the,world,s ... BIO,International Convention. Under the "Breakthroughs in Regenerative Medicines,in ... into the,latest research results in the area of ... the regulatory framework conditions will be,introduced in a ...
... Corporation (Nasdaq: MATK ) announced that it intends ... 2009 on June 3, 2009, at approximately 4:00 p.m. Eastern ... Martek will conduct a conference call to discuss these results ... call live via webcast by visiting Martek,s web site at ...
... North Carolina And ChinaRESEARCH TRIANGLE PARK, N.C., May ... Health Sciences has signed an agreement with China ... Institute for International Drug Development. Building on strengths ... development, and education, the Institute will help to ...
Cached Biology Technology:BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine 2The Hamner Institutes Announce Partnership With China Medical City 2The Hamner Institutes Announce Partnership With China Medical City 3
(Date:4/17/2014)... Researchers in France have hit on a novel ... receive the correct and most effective treatment possible., ... the western and developing world. If left untreated, ... to renal failure and other complications. In many ... problem. Clearly a more effective pathological approach to ...
(Date:4/17/2014)... Indiana University researchers have detected new early-warning signs of ... discovery could have far-reaching implications for the diagnosis and ... over 25 million Americans. , "We had not expected ... such early stages," said Ann Elsner, professor and associate ... author of the study. "We set out to study ...
(Date:4/17/2014)... have uncovered a new way the immune system may ... efforts to use immune cells to treat illness. , ... the immunological equivalent of "neighborhood police" specialized squads ... organ, instead of an entire city, the body. , ... Louis have shown that the liver, skin and uterus ...
Breaking Biology News(10 mins):New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Some immune cells defend only 1 organ 2
... Barbara, CA The Bren School-based authors of a study ... have observed toxicity to marine organisms resulting from exposure to ... toxic under similar conditions. Lead author and assistant research ... both Bren School professors and lead scientists at the ...
... at the University of California, Riverside discovered a tiny fairyfly wasp ... United States until then. Nearly exactly a year later, he ... is well established in the country. Called Gonatocerus ater ... North America from Europe. It lays its eggs inside the ...
... New Rochelle, NY, January 24, 2012The time for commercial development ... and curable with gene therapy deserve access to the technology, ... Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy ... . Human Gene Therapy and Human Gene ...
Cached Biology News:Nano form of titanium dioxide can be toxic to marine organisms 2Wasp found in upstate New York shows up in Southern California 2Gene therapy is a 'disruptive science' ready for commercial development 2